Sign In
Buy OTSKY
$32.95
-1.07 (-3.14%)
At Close: Jun 22, 2026
AstraZeneca (OTCMKTS:AZNCF) versus Otsuka (OTCMKTS:OTSKY) Financial Review
01:44am, Friday, 17'th Apr 2026
AstraZeneca (OTCMKTS:AZNCF - Get Free Report) and Otsuka (OTCMKTS:OTSKY - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the st
Otsuka Holdings Co., Ltd. (OTSKY) M&A Call Prepared Remarks Transcript
07:51pm, Friday, 10'th Apr 2026
Otsuka Holdings Co., Ltd. (OTSKY) M&A Call Prepared Remarks Transcript
Santen Pharmaceutical (OTCMKTS:SNPHY) & Otsuka (OTCMKTS:OTSKY) Financial Review
02:22am, Monday, 23'rd Mar 2026
Otsuka (OTCMKTS:OTSKY - Get Free Report) and Santen Pharmaceutical (OTCMKTS:SNPHY - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies b
Contrasting Otsuka (OTCMKTS:OTSKY) and Mayne Pharma Group (OTCMKTS:MAYNF)
02:44am, Saturday, 14'th Mar 2026
Mayne Pharma Group (OTCMKTS:MAYNF - Get Free Report) and Otsuka (OTCMKTS:OTSKY - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses
Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript
01:36pm, Thursday, 19'th Feb 2026
Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
07:30am, Thursday, 19'th Feb 2026
MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 20
Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
08:30am, Wednesday, 04'th Feb 2026
February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models
Recent Price Trend in Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) is Your Friend, Here's Why
09:55am, Monday, 26'th Jan 2026
If you are looking for stocks that are well positioned to maintain their recent uptrend, Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) could be a great choice.
Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) Is a Great Choice for 'Trend' Investors, Here's Why
09:55am, Monday, 29'th Dec 2025
If you are looking for stocks that are well positioned to maintain their recent uptrend, Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) could be a great choice.
Here's Why Momentum in Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) Should Keep going
09:56am, Thursday, 11'th Dec 2025
Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.
US FDA approves Otsuka's kidney disease drug
03:12pm, Tuesday, 25'th Nov 2025
The U.S. Food and Drug Administration has approved Otsuka's injectable drug to treat patients with a potentially life-threatening kidney disease, the health regulator's website showed on Tuesday.
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
08:00am, Monday, 10'th Nov 2025
Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive
EMERYVILLE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
08:00am, Friday, 19'th Sep 2025
Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL Third Largest Global Market for Cardiovascular Prevention Represents Significant
Otsuka Corporation (OSUKF) Q1 FY2025 Earnings Call Transcript
12:02pm, Saturday, 02'nd Aug 2025
Otsuka Corporation (OTCPK:OSUKF) Q1 FY2025 Earnings Conference Call August 1, 2025 2:30 AM ET Company Participants Yuji Otsuka - CEO, President, Chairman & MM Division Chief Yuji Otsuka I am Otsuka of
